Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | HPGD | P15428 | 2/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.80 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | GMNN | O75496 | 1/20 | 0.80 |
| ▸ | APEX1 | P27695 | 1/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.80 |
| ▸ | HTT | P42858 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R(+)Xk469 SCHEMBL1958606 | 1.00 | ALDH1A1 (0.80) | ALDH1A1CYP1A2MAPTHPGDNPSR1 | |
| R(+)Xk469 SCHEMBL30064428 | 1.00 | ALDH1A1 (0.80) | ALDH1A1CYP1A2MAPTHPGDNPSR1 | |
| R(+)Xk469 SCHEMBL31494114 | 1.00 | ALDH1A1 (0.80) | ALDH1A1CYP1A2MAPTHPGDNPSR1 | |
| Quizalofop SCHEMBL29763487 | 0.95 | ALDH1A1 (0.72) | ALDH1A1CYP1A2MAPTHPGDNPSR1 | |
| Quizalofop SCHEMBL19210826 | 0.95 | ALDH1A1 (0.72) | ALDH1A1CYP1A2MAPTHPGDNPSR1 | |
| Quizalofop SCHEMBL63325 | 0.95 | ALDH1A1 (0.72) | ALDH1A1CYP1A2MAPTHPGDNPSR1 | |
| Quizalofop SCHEMBL111413 | 0.95 | ALDH1A1 (0.72) | ALDH1A1CYP1A2MAPTHPGDNPSR1 | |
| Quizalofop SCHEMBL1010164 | 0.95 | ALDH1A1 (0.72) | ALDH1A1CYP1A2MAPTHPGDNPSR1 | |
| Quizalofop SCHEMBL10942454 | 0.94 | ALDH1A1 (0.71) | ALDH1A1CYP1A2MAPTHPGDNPSR1 | |
| Quizalofop SCHEMBL10847222 | 0.92 | CYP1A2 (0.69) | ALDH1A1CYP1A2MAPTHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024132001-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2024-06-27 | — | — | WO | disclosed |
| US-20150182452-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | ONCOSYNERGY INC (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150182452-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | ONCOSYNERGY INC (US) | 2015-07-02 | — | — | US | disclosed |
| US-8487004-B2 | Local treatment of neurofibromas | Nexgenix Pharmaceuticals, Inc. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487004-B2 | Local treatment of neurofibromas | Nexgenix Pharmaceuticals, Inc. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120315298-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | NEXGENIX PHARMACEUTICALS, INC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120315298-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | NEXGENIX PHARMACEUTICALS, INC (US) | 2012-12-13 | — | — | US | disclosed |
| US-8211875-B2 | Local treatment of neurofibromas | Nexgenix Pharmaceuticals Inc (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211875-B2 | Local treatment of neurofibromas | Nexgenix Pharmaceuticals Inc (US) | 2012-07-03 | — | — | US | disclosed |
| US-20090118240-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090118240-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315298-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | VHL, NGF, S100B | ALDH1A1 1085/4885CYP1A2 3765/4885MAPT 2945/4885 |
| US-20090118240-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | VHL, NGF, S100B | ALDH1A1 1085/4885CYP1A2 3765/4885MAPT 2945/4885 |
| US-20150182452-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | VHL, NGF, S100B | ALDH1A1 1085/4885CYP1A2 3765/4885MAPT 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.